Sensex hits 45,000 and Nifty scales fresh high as RBI revises growth outlook — these are the top movers in trade
- RBI’s growth optimism is driving markets to fresh highs in trade today
- Sensex scaled 45,000 mark for the first time ever, and the Nifty 50 too hit a fresh high at 13,222.
- Check out the latest news and updates on Business Insider.
RBI has raised the growth outlook, sees 7.5% GDP contraction for FY21. RBI Governor Shaktikanta Das said the growth will enter the positive territory in the third quarter of current fiscal with a projection that GDP may grow at 0.1% and the growth will further improve in Q4 to 0.7%.
Here’s a list of the top losers and gainers in the Nifty pack.
*as of December 4, 10:51 am
|Top Nifty Gainers||Top Nifty Losers|
These are the top stocks in news today.
Bharti Airtel shares trade 2% higher, Vodafone-Idea down over 2%
The shares of telecom giant Bharti Airtel gained over 2% after it added 3.77 million new customers in September, which is more than twice of what Reliance Jio added. However, the shares of Vodafone-Idea were down 2% as the company lost nearly 4.65 million subscribers.
SpiceJet trades 10% higher, IndiGo up nearly 5%
The shares of IndiGo and SpiceJet zoomed during the early trading hours on Friday. The rally came after the civil aviation ministry increased the cap on domestic flight capacity of airlines from 70% to 80% of pre-Covid levels.
NCC zooms over 6%
The shares of construction and engineering company, NCC zoomed nearly 6% after Rakesh Jhunjhunwala and family has increased stake in the company to 13.7% from 12.14% as of September 2020.
AdvertisementTata Power shares gain over 4%
The shares of Tata Power gained over 4% after the news reports surfaced that the company has emerged as the winner in bids for two electricity distribution companies (discoms) in Odisha—the Western Electricity Supply Utility of Odisha Ltd (WESCO) and the Southern Electricity Supply Utility of Odisha Ltd (SOUTCO).
Granules India trades 2% higher
AdvertisementThe shares of drug firm Granules India gained over 2% after its wholly-owned foreign subsidiary, Granules Pharmaceuticals Inc, has received approval from the US health regulator for its abbreviated new drug application (ANDA) for Penicillamine capsules USP, 250 mg. The drug is used for the treatment of Wilson’s disease and cystinuria.
SEE ALSO: A coordinated, global network of hackers tried to break into the COVID-19 'cold chain,' which transports vaccines at -94 degrees Fahrenheit
SBI’s mobile banking app is down for the third time in 30 days — digital services take a hit for the 25th time this year
- Google photos will charge $1.99 per month for 100 GB storage from June 1
- Best smartphones under ₹10,000 in India
- Tamil Nadu government to bear all expenses of COVID patients in private hospitals
- CoWin portal to make 4-digit security code mandatory from May 8